
With respective opportunities associated and held by our affiliates, R&D Investment has Continuously Increased with Remarkable Results in Innovation and Transformation

FOSUN PHARMA USA



- Pharmaceutical is the core business of Fosun Pharma
- In the first half of 2024, revenue from Pharmaceutical reached RMB**14.677** billion
- Revenue from key innovative products exceeded RMB3.7 billion
- R&D expenditure in the pharmaceutical manufacturing segment amounted to 2.406 billion
- R&D expenses were RMB1.572 billion



16.39%

Pharmaceutical

Innovative Medicines

- Focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation
- Strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules
- Establishes an open,
 globalized and
 innovative R&D model,
 continuously enhance
 pipeline value, and drive
 the R&D and
 commercialization of key
 products

3 Divisions

Specialization

Vaccine

Established Medicines Manufacturing & Supply

- With integrated development
 as the goal, focus on the R&D of
 differentiated and high-tech
 barrier products, and increase
 the proportion of first/first,
 difficult complex preparations
 and improved new drugs
- Promote the integration of production lines and capacity, continue to reduce costs and increase efficiency

An independent R&D system has been established with two major technology platforms, bacterial vaccines and viral vaccines as the core

Accelerates the market launch of self-developed vaccine products, further expands vaccine pipeline through cooperative development and enhances vaccine industrialization capabilities